Table 9. Activations resulting from the Ustop> Sstop contrast group comparisons (p <.005, k ≥ 13 voxels).
Region | Cluster | L/R | F | MNI coord, x, y, z |
---|---|---|---|---|
LOW DOSE VS. PLACEBO | ||||
Prefrontal Cortex | ||||
Paracentral lobule1 | 91 | L | 13.28 | -12-26 52 |
Paracentral lobule1 | 41 | R | 18.88 | 12-36 56 |
Temporal/Cerebellum | ||||
Superior temporal gyrus2 | 21 | R | 15.38 | 38 2-16 |
Middle Temporal1 | 30 | R | 26.3 | 38-58 2 |
Middle Temporal Pole2 | 22 | L | 20.13 | -24 0 -36 |
Parahippocampal gyrus2 | 69 | R | 24.95 | 22 -22 -22 |
Fusiform2 | 29 | R | 13.7 | 40 -40 -18 |
Cerebellum2 | 17 | R/L | 16.75 | 10-58 -10 (-14-72 -16) |
Subcortical areas | ||||
Caudate1 | 39 | L | 21.64 | -14 18 18 |
Thalamus2 | 15 | R | 11.67 | 8-28 6 |
HIGH DOSE VS. PLACEBO | ||||
Prefrontal Cortex | ||||
Posterior Cingulate1 | 50 | L | 28.38 | -10-42 16 |
Middle cingulate1 | 54 | R | 16.36 | 10-16 46 |
Ventral Anterior cingulate1 | 18 | L | 19.95 | -10 34 -8 |
Rostral Orbitofrontal (BA11) 2 | 13 | R | 16.15 | 10 54 -20 |
Superior Frontal gyrus (BA9) 2 | 21 | R | 15.25 | 10 44 46 |
Precentral gyrus1 | 24 | R | 14.85 | 16-22 58 |
Precentral gyrus1 | 13 | R | 13.69 | 30 -6 46 |
Postcentral gyrus1 | 15 | R | 17.24 | 24-36 48 |
Temporal cortex | ||||
Parahippocampal gyrus2 | 41 | R | 25.53 | 24 -22 -22 |
Inferior temporal gyrus1 | 32 | R | 22.14 | 44-46 -14 |
Subcortical regions | ||||
Thalamus2 | 21 | R | 15.84 | 6-8 18 |
HIGH DOSE VS. LOW | ||||
Prefrontal Cortex | ||||
Middle frontal gyrus4 | 13 | R | 19.27 | 36 62 2 |
Paracentral Lobule3 | 38 | R | 18.61 | 2-32 72 |
Postcentral gyrus3 | 31 | R | 15.66 | 42 -26 56 |
Parietal/Temporal cortex | ||||
Superior Parietal3 | 43 | L | 16.84 | -22-52 56 |
Cuneus3 | 32 | L | 14.65 | -18-70 38 |
Inferior temporal3 | 66 | R | 19.2 | 46 -44 -22 |
Parahippocampal gyrus3 | 13 | R | 12.6 | 18 -6 -22 |
Cerebellum3 | 21 | R | 18.94 | 38-66 -26 (12-38 -22/38 -64-40) |
BA = Broadmann area; R = right, L = left; MNI coordinates represent cluster peaks; Results: 1Increased, 2Decreased activation relative to placebo; 3Increased, 4Decreasedactivationrelativetothelowdose.